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Peroxisome proliferator-activated receptor gamma (PPARγ) is a ligand-activated transcription factor, which belongs to the family
of nuclear hormone receptors. Recent in vitro studies have shown that PPARγ can regulate the transcription of phosphatase
and tensin homolog on chromosome ten (PTEN), a known tumor suppressor. PTEN is a susceptibility gene for a number of
disorders,includingbreastandthyroidcancer. ActivationofPPARγ throughagonistsincreasesfunctionalPTENproteinlevelsthat
subsequentlyinducesapoptosisandinhibitscellulargrowth,whichsuggeststhatPPARγ maybeatumorsuppressor.Indeed,several
in vivo studies have demonstrated that genetic alterations of PPARγ can promote tumor progression. These results are supported
by observations of the beneﬁcial eﬀects of PPARγ agonists in the in vivo cancer setting. These studies signify the importance of
PPARγ and PTEN’s interaction in cancer prevention.
Copyright © 2008 R. E. Teresi and K. A. Waite. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
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1. INTRODUCTION
1.1. PPARγ
Peroxisome proliferator-activated receptor gamma (PPARγ)
is a ligand-activated transcription factor, belonging to the
nuclear hormone receptor family, whose ligand-binding
domain is located at the carboxy-terminus. There are several
known natural and synthetic PPARγ agonists with 15-
deoxy-delta 12, 14-prostaglandin-J2 (15d-PG-J2) being the
most notable natural PPARγ agonist. Additionally, linoleic,
linolenic, and arachidonic acids are other commonly rec-
ognized natural agonists. Synthetic PPARγ agonists, such
as the thiazolidinediones (TZDs), are some of the most
commonly prescribed medications for the treatment of type
II diabetes mellitus. The fourcommerciallyrecognized TZDs
are ciglitazone (Alexis), pioglitazone (Actos), rosiglitazone
(Avandia), and troglitazone (Rezulin).
After ligand-activation, PPARγ forms a heterodimer
complex with retinoic acid receptor (RXR). This
PPARγ/RXR complex subsequently translocates to the
nucleus and binds to a peroxisome proliferator response
element (PPRE) within a target gene thereby initiating
transcription. The primary, and most studied, targets of
PPARγ are involved in metabolic pathways and adipocyte
diﬀerentiation. However, in recent years it has been
suggested that PPARγ has a role in cancer development.
Indeed, initial studies demonstrated alterations of cellular
diﬀerentiation, indicative of apoptosis in a breast cancer
setting, after PPARγ agonist stimulation. This indicates that
PPARγ and its agonists may play an important role in cancer
development, prevention, and treatment.
In 1998, Mueller et al. performed one of the ﬁrst PPARγ
agonist studies in a cancer setting [1]. They demonstrated
that both 15d-PG-J2 and rosiglitazone (Rosi) could induce
changes in epithelial gene expression associated with a more
diﬀerentiated, less malignant state. Moreover, they described
a reduction in the overall growth rate of breast cancer cells
when treated with a PPARγ agonist. These data suggest
that PPARγ can contribute to the prevention of breast
cancer development and its agonists may be a novel therapy
for cancer treatment [1]. These results stimulated further
studies investigating PPARγ-mediated tumor suppression.
One protein, that may play a role in PPARγ-mediated
tumor suppression, is phosphatase and tensin homolog on
chromosome ten (PTEN), which has an established role
in breast cancer development. Interestingly, Mueller et al.
characterization of breast cancer cells after PPARγ activation
demonstrated a striking resemblance to cells with active
PTEN expression [1]. Taken together, these results suggested2 PPAR Research
thatPTENandPPARγ,together,maymodulatebreastcancer
progression.
1.2. PTEN
In 1995, PTEN was identiﬁed as the susceptibility gene for
Cowden syndrome (CS), which is characterized by breast,
thyroid, and endometrial carcinoma as well as macrocephaly
[2–8]. Patients diagnosed with CS have a 25–50% lifetime
risk of developing female breast cancer, compared to the
general population risk of ∼13% [9, 10] Additionally,
patients have ∼10% lifetime risk of developing thyroid
cancer, compared to <1% in the general population and
havea ∼5–10%lifetimeriskofendometrialcancercompared
to ∼2–4% in the general population [9, 11]. Since its
identiﬁcation, research has detected a PTEN mutation in
85% of CS patients [11]. Furthermore, somatic alterations
in PTEN, whether by genetic or epigenetic mechanisms, play
some role in the pathogenesis of a broad range of solid
tumors,includingsporadiccarcinomasofthebreast,thyroid,
endometrium, and colon.
PTEN’s protein, PTEN, is a unique phosphatase that
has the ability to dephosphorylate both proteins and
lipids (Figure 1)[ 4]. Its lipid phosphatase activity func-
tions as a negative regulator of Akt phosphorylation (P-
Akt). PTEN dephosphorylates phosphatidylinositol-3,4,5-
triphosphate (PIP3) at the D3 position generating phos-
phatidylinositol 4,5-biphosphate (PIP2), decreasing cellular
PIP3 levels. Since PIP3 is required for Akt phosphorylation,
active PTEN leads to a decrease in the levels of P-Akt
and consequently a decrease in Akt-mediated proliferation
pathways. PTEN’s protein phosphatase activity has been
shown to inhibit the SHC/SOS/GRB2 and mitogen-activated
protein kinase (MAPK) pathways. The dephosphorylation of
SHC by PTEN indirectly decreases the phosphorylated form
of MAPK levels, reducing MAPK’s activity. Additionally,
PTEN’s protein phosphatase activity upregulates p27 with a
concomitant downregulation of cyclin D1 which coordinates
G1 arrest [12]. By regulating these key-signaling pathways,
PTENdownregulatescelldivisionandupregulatesapoptosis.
Additionally, PTEN’s protein phosphatase activity has been
shown to dephosphorylate focal adhesion kinase (FAK),
which inhibits cell spreading and migration [4].
Transcriptional regulation of PTEN is only beginning to
be elucidated. To date, analysis of PTEN’s promoter suggests
that there are at least eight regulatory factors that modulate
PTEN’s transcription (Figure 2). In 2001, Stambolic et al.
identiﬁed a functional p53 binding site, located at nucleotide
positions −1190 to −1157 in PTEN’s promoter, which was
required for PTEN’s upregulation [13]. Additionally, early
growth response-1 (Egr-1) has been shown to bind to
the PTEN promoter at −947 to −939 and induce PTEN
expression [14]. Recently, our laboratory has identiﬁed a
USF1 binding site ∼2kb (−2237 and −2058) upstream of
the ATG site [15]. CBF-1, Sp1, and c-Jun have also recently
been suggested as PTEN transcription factors [11, 16–18].
The majority of PTEN promoter analyses have been focused
on transcription factors that increase PTEN levels. However,
recently, suppression of PTEN gene expression has been
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Figure 1: PTEN protein signaling pathways. PTEN’s lipid phos-
phatase activity dephosphorylates PIP3 to PIP2 inhibiting PDK1-
mediated Akt phosphorylation and downregulating Akt-mediated
cell survival. PTEN’s protein phosphatase activity inhibits the
phosphorylation of FAK to prevent cell migration. PTEN’s protein
phosphatase activity also dephosphorylates the SHC/SOS/GRB2
complex resulting in the decreased phosphorylation of MAPK and
inhibition of the cell cycle.
shown by the tumor necrosis factor-alpha/nuclear factor-
kappa B (NF-κB) [19], however the precise mechanism of
this inhibition remains unclear.
1.3. PPARγ andPTENinvitro
In 2001, Patel et al. ﬁrst showed that PPARγ can be a
PTEN transcription factor [20]. They observed that Rosi
induced PTEN protein expression in both MCF-7 breast and
CoCa2 colon cancer cell lines. In addition to the increase
in PTEN expression, they observed an inhibition of both
Akt phosphorylation and cellular proliferation. They also
identiﬁed two putative PPREs within the PTEN promoter
approximately 15 and 13kb upstream of the ATG site
(Figure 2). While this study was signiﬁcant in demonstrating
a potential link between PPARγ and PTEN, it remained
correlative.
In 2005, two independent laboratories conﬁrmed Patel’s
suspicion that PPARγ induces PTEN transcription in a
breast cancer setting [21, 22]. We demonstrated that of
the four TZDs, only Rosi had the ability to induce PTEN
transcription and subsequently its protein expression in
MCF-7 cells [21]. Furthermore, we showed that stimulation
with Rosi induces a PTEN protein that is both protein-
and lipid-phosphatase active, as evidenced by decreased
phosphorylation of Akt and MAPK concomitant with PTEN
expression. Additionally, Rosi treatment induced G1 arrest
thatparalleledwithPTENexpression.ByusingaRosianalog,
Compound 66, that is incapable of activating PPARγ,w e
conﬁrmed that Rosi induced PTEN expression via a PPARγ-
dependent mechanism in several reporter assays [21].
Additionally, in 2005, Bonoﬁglio et al. also demonstrated
that PPARγ could upregulate PTEN’s transcription in a
breast cancer setting [22]. After cells were stimulated withR. E. Teresi and K. A. Waite 3
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Figure 2: PTEN promoter and its transcription factors. PTEN’s full-length promoter lies between −1344 and −745 (gray bar), while the
minimalpromoterliesbetween −958and −821(blackbar).FourtranscriptionfactorsareknowntodirectlybindupstreamofPTEN:PPARγ
(solid gray bar), USF1 (stripped gray bar), p53 (dotted gray bar), and EGR1 (dashed gray bar).
Rosi, an increase in PTEN protein was observed as well as
an inhibition of Akt phosphorylation and cellular growth.
More importantly, they were able to observe for the ﬁrst
time the speciﬁc binding of PPARγ to the PTEN promoter
(−15376 to −15364; Figure 2). Interestingly, this interaction
was enhanced by Rosi treatment. Further analysis indicated
that PPARγ and estrogen receptor (ER) could bind to the
PPRE both independently and simultaneously. The ER’s
association with the PPRE inhibited PPARγ’s ability to
induce transcription as demonstrated by cotreatment of
MCF-7 breast cancer cells with both Rosi and 17ß-estradiol.
This cotreatment inhibited the induction of PTEN protein
that was observed by Rosi stimulation alone [22]. This is an
important observation as it is appealing to postulate that this
crosstalk, between PPARγ and ER, may signiﬁcantly aﬀect
breast cancer therapeutics as well as lead the way to the
discovery of future novel treatment therapies.
In 2006, Zhang et al. showed that Rosi stimulation of
hepatocarcinoma cells results in the upregulation of PTEN
and PTEN-dependent inhibition of cell migration [23].
This is signiﬁcant because PTEN expression is decreased or
absent in approximately half of all primary hepatocarcinoma
patients.Assimilarlydemonstratedbyothers,Rositreatment
of hepatocarcinoma cells resulted in an increase in PTEN
mRNA. They further speculated that there may be three
other potential PPREs within the PTEN promoter, located
at −2874 to −2854, −1615 to −1596, and −1594 to
−1574, however, it has not yet been determined if these are
functional PPREs. Interestingly, Zhang et al. do not observe
an increase in transcriptional activity of the PTEN promoter
in response to Rosi treatment [23]. We observed similar
results when examining the full-length PTEN promoter,
using a luciferase reporter assay and Rosi stimulation (Teresi,
Waite,andEng;unpublishedobservations).Thismaysuggest
that elements beyond the full-length PTEN promoter are
required for Rosi-mediated PTEN transcription.
TheseinitialstudiesconcretelydemonstratedthatPPARγ
actsasatumorsuppressorinacancersettingbyupregulating
PTEN transcription. However, these studies were performed
solely in breast cancer cell lines, leaving the speculation
that these observations are cancer-type dependent. To this
end, several groups have studied PPARγ’s ability to regu-
late PTEN levels in other cancer backgrounds. Lee et al.
observed an inhibition of cellular proliferation and Akt
phosphorylation in accord with an increase in G1 arrest and
PTEN protein expression in A549 lung cancer cells [24].
Subsequently, PPARγ has been shown to upregulate PTEN
expression in nonsmall cell lung cancer, neuroblastoma,
adrenocortical, pancreatic, heptocarcinoma, and thyroid cell
lines [23, 25, 26].
Interestingly,themajorityofthesestudiesutilizedRosias
the PPARγ agonist. This may be due to the combination of
our initial study, which demonstrated that of the TZDs only
Rosi was capable of inducing PTEN expression, and the fact
thatnaturalligandscanbediﬃculttoworkwithinvitro[21].
Despite this, Chen et al. demonstrated that both ciglitazone
and 15d-PG-J2 could upregulate PTEN expression in W-2
thyroid cells [27], which raises the possibility that of the
TZDs, Rosi stimulation is limited to breast cancer. This
remains to be determined.
1.4. PPARγ andPTENinvivo
Despite the growing amount of in vitro data supporting
the role of PPARγ as a tumor suppressor, only a small
numberofcancershavehadtheirPPARγ statuscharacterized
in vivo and there are very few studies of clinical PPARγ
agonist treatment. Nonetheless, current studies provide
some essential and encouraging information. One of the
ﬁrst studies to analyze PPARγ s t a t u si na ni nv i v oc a n c e r
settingexamined55unrelatedsporadiccoloncancersamples
and revealed 4 PPARγ mutations [28]. Moreover, these
mutations produced an inactive PPARγ protein. This study
demonstrated that PPARγ can act as a tumor suppressor
in vivo and when its normal activity is altered it can
lead to cancer development [29]. Subsequent studies have
conﬁrmed these results showing the reduction of PPARγ
expressioninbothacrometaly[30]andulcerativecolitis[31],
two predisposing conditions of colon cancer. In contrast
to these studies, Ikezoe et al. did not observe any PPARγ
alterations in their colon cancer study; however they limited
their study to only exons 3 and 5 of PPARγ [32]. These
studies indicate that PPARγ is indeed a tumor suppressor in
thecoloncancersetting;howevernoneofthesestudiestested
if the TZDs could eﬀect the cancer’s progression.
To date, the majority of studies correlating PPARγ with
PTENhavebeenperformedinvitroandthesestudiessuggest
that PPARγ agonists may be beneﬁcial to PTEN in vivo.
Moreover, in vitro data suggest that PPARγ agonists have
the potential to be highly eﬀective PTEN transcriptional
inducers for patients who have one of the following: a
hemizygousdeletion,agermlinenucleotidealterationwithin4 PPAR Research
the promoter, and potentially in the circumstance, where a
PTEN mutation is not identiﬁed but a decrease in protein
expression is observed.
Despite the potential beneﬁcial eﬀects of TZD treatment,
in particular Rosi, one must be aware that the use of these
medicationsmayleadtomoreharmthangood.Forexample,
treatment of patients with germline intragenic PTEN muta-
tions or those with neoplasias containing somatic intragenic
mutations may see a raise of mutant, inactive protein.
Recently, PTEN has been shown to induce gain-of-function
p53 protein suggesting that TZD treatment in this setting
may subsequently induce mutant, nonbeneﬁcial p53 protein.
Additionally, our work and others have suggested that not all
of TZDs signal through the same pathways, at least in cell
culture conditions [21]. Rosi is the only TZD that is known
to increase PTEN in breast cancer lines, which indicates that
each TZD may lead to its own individual side eﬀects. Indeed
in 2000, troglitazone (Rezulin) was pulled oﬀ of the market
due to liver toxicity. Interestingly, to date, this has not been
observedwithotherTZDs[33].Arecentstudydemonstrated
that Rosi (Avandia) increases the risk of heart complications,
speciﬁcally heart attacks; however these results have yet to
be replicated [34]. This indicates that the signiﬁcance of
Rosi treatment on cardiac function needs to be examined
further. Indeed, in this ﬁrst study, important results, which
came to the opposite conclusions, were not included in the
meta-analysis. In spite of this, a deeper understanding of
the signaling mechanisms behind these side eﬀects should
open the door to both new avenues of cancer treatment
and personalized health care, allowing physicians to properly
weigh the beneﬁts against the known side eﬀects prior to
prescribing such a treatment.
Drug-drug interactions are another aspect that physi-
cians will need to be aware of. Bonoﬁglio’s PPARγ-ER-PTEN
results are signiﬁcant in the context of breast cancer and
hormone therapies [22]. Their data suggest that women
treated with hormones, either through birth control or
hormonal therapies, may not beneﬁt from cotreatment
with a PPARγ agonist. This further suggests that hormone
treatmentmayactuallybedetrimentalbyinhibitingnaturally
occurring PTEN transcription.
1.5. ThetranslationofPPARγ andPTENintotheclinic
A recent study has suggested that Rosi treatment could be
beneﬁcial to patients with Geﬁtinib-resistant lung cancer
[24], a cancer which is typically correlated with the loss of
PTEN protein. Lee et al. have shown that in the human lung
cancer cell line, A549, the combined treatment of Rosi and
Geﬁtinib was more beneﬁcial than Geﬁtinib treatment alone
[24]. Taken together, these data provide support that the
upregulationofPTENlevelswithRositreatmentmayreverse
the Geﬁtinib resistance in these patients. Such a treatment
could have the potential to be advantageous to patients with
both sporadic and familial cancer.
PPARγ status is only now beginning to be examined in
the in vivo cancer setting, however the TZDs have been used
in a variety of clinical trials, although not directly related to
PPARγ activation. Seemingly, out of the ordinary, polycystic
ovary syndrome (PCOS) is the most commonly studied
syndrome with regards to the eﬀects of TZD treatment
[35]. While there is still much debate on what treatment
is best for these patients, the majority believe that Rosi
treatment is beneﬁcial. Studies have demonstrated that Rosi
treatment raises insulin and androgen levels in the obese
PCOS population, thereby inhibiting tumor progression.
Furthermore, Yee et al. recently performed a pilot study in
women with breast cancer to determine if Rosi treatment
would be beneﬁcial. Thirty-eight women with early stage
breast cancer were treated with Rosi for 2–6 weeks with
tumorgrowthinhibitionorprogressionasanendpoint[36].
The data indicate that short-term Rosi therapy in early-stage
breast cancer patients has both local and systemic eﬀects on
PPARγ signaling. Both of these studies suggest that Rosi may
be used clinically to beneﬁt cancer patients.
1.6. PPARγ andPTEN’sfuture
The culmination of these data strongly suggests that Rosi
stimulation may be advantageous to the cancer patient.
However, lacking in many of these studies is the role of
PTEN. To date, in vitro data has demonstrated a connection
between PPARγ a n dP T E N ,y e tn oi nv i v os t u d yh a s
concretelyconﬁrmedtheseresults.Theresultsobtainedfrom
these studies would concretely determine if Rosi treatment
is advantageous for cancer patients by upregulating PTEN
expression through PPARγ.
While clinical trials are necessary to determine if Rosi
treatment is truly beneﬁcial for cancer patients and which
patients it is most advantageous for, much remains to be
learned at the molecular level. The relevance of the putative
PPRE in the PTEN promoter identiﬁed by Bonoﬁglio et
al. remains to be determined (Figure 2)[ 22]. This PPRE
is located a long distance from the ATG site, thus making
it unclear if this site is functional in regulating PTEN
expression. It will be interesting to ﬁnd out the role of this
unique site.
While evidence suggests that TZDs induce PTEN
expression through PPARγ, further studies are warranted
to determine the exact mechanism of action. Evidence
by our group suggests that PPARγ may regulate PTEN
expression through both transcriptional-dependent and
-independent mechanisms [37]. While this may add to the
complexity of the role of PPARγ, with regards to PTEN,
it may also provide other areas for therapeutic advances.
Interestingly, while studying the ability of statins to induce
PTEN expression, we observed that statins increase PTEN
transcription via an unknown PPARγ-mediated mechanism
[37]. Retrospectively, we observed a similar response with
RosistimulationindicatingthatPPARγ isnecessary;however
its transcriptional activity is not. These results suggest
that PPARγ may induce PTEN transcription through an
unknown mechanism and an unrecognized transcription
factor; however this remains to be determined.
2. CONCLUSION
In recent years, there has been a growing accumulation of
dataimplicatingtheimportanceofbothPPARγ andPTENinR. E. Teresi and K. A. Waite 5
cancerprevention,development,andtreatment.Invitrodata
hasdemonstratedthatPPARγ agonistscaninducefunctional
PTEN protein that controls cellular growth. In vivo data
has suggested that PPARγ genetic alteration can lead to
cancer development, while its agonists can inhibit tumor
progression. Despite this progress, we are only beginning to
determine the roles of these two proteins and their complex
interactions. Undoubtedly, future studies will clarify the
PPARγ-PTEN connection providing a variety of targets that
may lead to novel therapeutic treatments for cancer patients.
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